Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study

Jahr

2025

Autoren

Garthof S, Schäfer S, Elmers J, Schwed L, Linz N, Boggiano T, Chatham C, Overell J, Hayward-Koennecke H, Tröger J, Dillenseger A, Tackenberg B, Ziemssen T.

Verlag

Mult Scler. 2025 Jun;31(7):856-865.

Link

https://doi.org/10.1177/13524585251329801

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study

Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment

Serum glial fibrillary protein reflects early brain injury dynamics and cognitive changes after deep brain stimulation surgery